Tarsus Pharmaceuticals, Inc. (TARS)
TARS Stock Price Chart
Explore Tarsus Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze TARS price movements and trends.
TARS Company Profile
Discover essential business fundamentals and corporate details for Tarsus Pharmaceuticals, Inc. (TARS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
323.00
Website
https://www.tarsusrx.comCEO
Bobak R. Azamian
Description
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS Financial Timeline
Browse a chronological timeline of Tarsus Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.20, while revenue estimate is $169.49m.
Earnings released on 6 May 2026
EPS came in at -$0.16 surpassing the estimated -$0.40 by +60.17%, while revenue for the quarter reached $162.05m , beating expectations by +8.33%.
Earnings released on 23 Feb 2026
EPS came in at -$0.20 falling short of the estimated -$0.10 by -94.17%, while revenue for the quarter reached $151.67m , beating expectations by +4.91%.
Earnings released on 4 Nov 2025
EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%, while revenue for the quarter reached $118.70m , missing expectations by -17.93%.
Earnings released on 6 Aug 2025
EPS came in at -$0.48 falling short of the estimated -$0.33 by -45.45%, while revenue for the quarter reached $102.66m , missing expectations by -9.19%.
Earnings released on 1 May 2025
EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%, while revenue for the quarter reached $78.34m , missing expectations by -20.97%.
Earnings released on 25 Feb 2025
EPS came in at -$0.60 surpassing the estimated -$0.68 by +11.76%, while revenue for the quarter reached $66.41m , beating expectations by +3.04%.
Earnings released on 13 Nov 2024
EPS came in at -$0.61 surpassing the estimated -$0.94 by +35.09%, while revenue for the quarter reached $48.12m , beating expectations by +11.43%.
Earnings released on 8 Aug 2024
EPS came in at -$0.88 surpassing the estimated -$0.98 by +10.20%, while revenue for the quarter reached $40.81m , beating expectations by +28.91%.
Earnings released on 8 May 2024
EPS came in at -$1.01 surpassing the estimated -$1.15 by +12.17%, while revenue for the quarter reached $27.61m , beating expectations by +58.16%.
Earnings released on 27 Feb 2024
EPS came in at -$1.31 surpassing the estimated -$1.37 by +4.38%, while revenue for the quarter reached $13.08m , beating expectations by +131.02%.
Earnings released on 9 Nov 2023
EPS came in at -$1.28 surpassing the estimated -$1.40 by +8.57%, while revenue for the quarter reached $1.87m , missing expectations by -68.50%.
Earnings released on 10 Aug 2023
EPS came in at -$1.17 falling short of the estimated -$1.08 by -8.33%, while revenue for the quarter reached $15.28m , beating expectations by +768.01%.
Earnings released on 9 May 2023
EPS came in at -$0.88 surpassing the estimated -$0.95 by +7.37%, while revenue for the quarter reached $2.50m , missing expectations by -19.87%.
Earnings released on 13 Mar 2023
EPS came in at -$0.49 surpassing the estimated -$0.97 by +49.48%, while revenue for the quarter reached $10.00m , meeting expectations.
Earnings released on 9 Nov 2022
EPS came in at -$0.84 surpassing the estimated -$0.98 by +14.29%.
Earnings released on 11 Aug 2022
EPS came in at -$0.24 surpassing the estimated -$0.65 by +63.08%, while revenue for the quarter reached $15.28m , beating expectations by +35.80%.
Earnings released on 10 May 2022
EPS came in at -$0.98 falling short of the estimated -$0.87 by -12.64%, while revenue for the quarter reached $539.00k , missing expectations by -89.63%.
Earnings released on 14 Mar 2022
EPS came in at -$0.72 surpassing the estimated -$0.77 by +6.49%, while revenue for the quarter reached $338.00k , missing expectations by -81.89%.
Earnings released on 9 Nov 2021
EPS came in at -$0.76 falling short of the estimated -$0.65 by -16.92%, while revenue for the quarter reached $1.24m , missing expectations by -76.74%.
Earnings released on 4 Aug 2021
EPS came in at $0.33 surpassing the estimated -$0.48 by +168.75%, while revenue for the quarter reached $22.02m , meeting expectations.
TARS Stock Performance
Access detailed TARS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
